Aggressive traders looking for solid ideas with big upside from all over Wall Street will like a new research note from Stifel, which features four stocks to buy with huge potential.
Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.
Valeant Pharmaceuticals reported its third-quarter financial results before the markets opened on Monday.
Chris Lange Over the past week, a few biotech companies, such as Cepheid and Valeant Pharmaceuticals, made absolutely massive runs.
Chris Lange We scanned the Merrill Lynch stock coverage universe for specialty pharmaceutical stocks rated Buy and found three top companies that have been crushed.
Friday’s top analyst upgrades, downgrades and initiations include AIG, Facebook, Gilead Sciences, Google, Regeneron Pharmaceuticals, Twitter, Valeant Pharmaceuticals and Vertex Pharmaceuticals.
A report on Wednesday from Janney Capital Markets has targeted several iotech bcompanies it believes are now grossly oversold.
The Wall Street Journal reported Thursday morning that Canada-based Valeant Pharmaceuticals is preparing to pay $1 billion for the closely held Sprout Pharmaceuticals.
Paul Ausick Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
Whether insiders are diving for beaten-down shares or just adding to existing holdings, the solid buying we saw this week indicates that while the bull may be getting tired, there may still…
If there ever was a perfect storm for large pharmaceutical and big-cap biotech companies to make acquisitions to enhance growth it is now.
Despite the shortened trading week and the markets again hitting and falling back from record highs, the insider buying has stayed very consistent as we head into the summer.
While few people may want to admit it, but more and more cosmetic surgery and treatments are being done every year. The sales potential is in the billions.
Lee Jackson Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based on a new price for Salix shares.
A new bid from Endo International has made the merger situation around Salix Pharmaceuticals much more complicated.
